

PCT

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68	A2	(11) International Publication Number: WO 99/01572 (43) International Publication Date: 14 January 1999 (14.01.99)
(21) International Application Number: PCT/CA98/00633 (22) International Filing Date: 3 July 1998 (03.07.98) (30) Priority Data: 60/051,643 3 July 1997 (03.07.97) US 60/086,020 18 May 1998 (18.05.98) US 60/090,276 22 June 1998 (22.06.98) US (71) Applicant (for all designated States except US): ID BIOMEDICAL CORPORATION [CA/CA]; 8855 Northbrook Court, Burnaby, British Columbia V5J 5G1 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): BEKKAOUL, Faouzi [CA/CA]; 3877 Gilpin Street, Burnaby, British Columbia V5G 2H2 (CA). CLONEY, Lynn, P. [CA/CA]; 5438 Elizabeth Street, Vancouver, British Columbia V5Y 3J8 (CA). (74) Agents: NASSIF, Omar, A. et al.; Gowling, Strathy & Henderson, Suite 4900, Commerce Court West, Toronto, Ontario M5L 1J3 (CA).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: METHODS FOR RAPIDLY DETECTING METHICILLIN RESISTANT STAPHYLOCOCCI (57) Abstract Compositions and methods are provided for determining the presence of an antibiotic resistant <i>mecA</i> gene in a biological sample, comprising the general steps of (a) treating cells contained within a biological sample to expose target single-stranded nucleic acid molecules; (b) reacting the target single-stranded nucleic acids with a scissile link-containing nucleic acid which is complementary to a portion of an antibiotic resistant <i>mecA</i> gene, and with an enzyme which cleaves double-stranded target-probe complexes, under conditions which allow the target and probe to hybridize to each other to form a double-stranded target-probe complex, the enzyme molecule being capable of cleaving the scissile link of the target-probe complex such that one or more fragments of the nucleic acid probe released from said complex; and (c) determining whether cleaved portions of the detecting probe fragments released from said nucleic acid probe are produced, and thereby detecting the presence of the antibiotic resistant <i>mecA</i> gene.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

METHODS FOR RAPIDLY DETECTING METHICILLIN RESISTANT STAPHYLOCOCCI

TECHNICAL FIELD

- 5 The present invention relates generally to medical diagnostics, and more specifically, to methods, probes and primers for detecting the *mecA* gene of methicillin resistant staphylococci.

BACKGROUND OF THE INVENTION

- 10 Methicillin-resistant *Staphylococcus aureus* (MRSA) is an extremely virulent antibiotic-resistant form of *Staphylococcus aureus* which has been rapidly spreading worldwide. MRSA has been found to be common in many hospitals, with a prevalence ranging from less than 1% to greater than 80% (Pittet and Waldvogel, *Q. J. Med.* 239-241, 1997). Unfortunately, MRSA is no longer considered only a hospital associated pathogen, since community-acquired MRSA is also increasing.
- 15 Resistance to methicillin by *Staphylococcus aureus* is caused by the expression of a low affinity penicillin binding protein (PBP) called PBP2a or PBP2', in addition to the usual PBPs (Hartman and Tomasz, *J. Bacteriol.* 158:513-516; 1984; Murakami and Tomasz, *J. Bacteriol.* 171:874-879, 1989). The responsible *mecA* gene which encodes the PBP2', *mecA*, is present in resistant strains but not susceptible ones.
- 20 (Hartman and Tomasz, *J. Bacteriol.* 158:513-516, 1984; Matsushashi et al., *J. Bacteriol.* 167: 975-980, 1986), and has only a slight sequence variation from strain to strain (Ryffel et al., *Gene* 94:137-138, 1990). MRSA strains carrying the *mecA* gene also tend to demonstrate resistance to other antibiotics such as aminoglycosides, macrolides, quinolones, beta-lactams, monobactams, imipenem, meropenem (Maple et al., *Lancet* 25 *I*:537-540, 1989; Kayser, *Chemotherapy* 42 (suppl 2):2-12; Chambers et al. cited in Bowler, *Q. J. Med.* 90:243-246, 1997).

- Some *S. aureus* strains may exhibit heterogeneity of expression of the *mecA* gene (Hartman et al., *Antimicrob. Agents Chemother.* 29:85-92, 1986; Hiramatsu et al., *Microbiol. Immunol.* 36:445-453, 1992; Ryffel et al., *Antimicrob. Agents*
- 30 *Chemother.* 38:724-728, 1994). Within these populations, although all cells carry *mecA*, the majority of cells are susceptible to low concentrations of the antibiotic and only a minority of the cells (1 in 10⁵ -10⁶) express resistance (Hackbarth et al., *Antimicrob. Agents Chemother.* 33:991-994, 1989; Ryffel et al., *Antimicrob. Agents Chemother.* 38:724-728, 1994). Consequently, these strains exhibit low MIC and may

be incorrectly characterized as sensitive to methicillin. Conversely, some *S. aureus* strains that lack the *mecA* gene may display borderline or low level resistance to methicillin due to alternate mechanisms of resistance (Chambers et al., *Antimicrob. Agents Chemother.* 33:424-428, 1989; Hiramatsu et al., *Supra*). Low level resistance to methicillin due to hyper β -lactamase production, methicillinase production, or the synthesis of modified PBP (Knapp, et al, *J. Clin. Microbiol.* 34:1603-1605, 1996; McDougal, et al., *J. Clin. Microbiol.* 23:832-839, 1986; Tomasz et al., *Antimicrob. Agents Chemother.* 33:1869-1874, 1989.) may be incorrectly diagnosed as MRSA by conventional susceptibility tests.

10 Rapid detection, both for prevention of transmission and treatment of methicillin resistant *Staphylococcus* (MRS) species has become a worldwide priority. There are a number of techniques available in the diagnostic field for detecting MRS, including conventional biochemical tests and immunological tests. For example, one accepted method for detection of MRS is the screening for isolates on Mueller-Hinton
15 agar containing 4% NaCl and 6 μ g/ml of oxacillin. Many laboratories now use automated screening systems such as Microscan API (Dade) and Vitek GPS-SA card (bioMerieux, Hazlewood, MO) which give susceptibility results within 24 hours (Knapp et al., *Supra*). The BBL[®] Crystal[™] MRSA ID test (Beckton Dickinson, Cockeysville, MD) is a more rapid susceptibility test that permits diagnosis after 4 to 6
20 hours (Wallet et al. *J. Antimicrobiol. Chemother.* 37:901-909; Martinez et al, *Rev. Esp. Quimioterap.* 9:130-133, 1996). However, none of the susceptibility tests can reliably differentiate between heterogeneous MRSA and borderline oxacillin resistant *S. aureus* (BORSA, Knapp et al., *Supra*; Lencastre et al., *Eur. J. Clin. Microbiol. Infect. Dis.* 12:S13-S18).

25 Many of these techniques also have drawbacks related to time, lack of specificity and sensitivity of detection. To address such issues, detection of the *mecA* gene utilizing the polymerase chain reaction ("PCR") has also been attempted. Briefly, PCR has been used in several studies for detecting the *mecA* gene, but test results using this method are expensive and can take up to 6 hours (Wallet, *Supra*). In addition, there
30 are a number of problems associated with such methods, including background contamination, carry over contamination, thermocycling, special room requirements, cumbersome from the point of view of the number of primers and probes required, number of steps and time involved in processing the samples and the special training required. In spite of the wide use of PCR in the molecular biology area due to its high
35 sensitivity and multiple applications there are only a few FDA approved PCR or other target amplification based diagnostic products. The main factor limiting the use of these

technologies in clinical diagnostic setting is the inherent problem of amplicon contamination. There are several chemical or physical methods that were developed to reduce or eliminate the problem of contamination. Generally these methods add extra steps and are costly.

- 5 Although the above methods can be used to detect MRSA, there is an urgent need for a rapid, user friendly and reliable method for detecting the *mecA* gene in nosocomial and non-nosocomial settings. The present invention provides probes, primers and methods for detecting the *mecA* gene that meet these needs. Further, the present invention provides other, related advantages.

10 SUMMARY OF THE INVENTION

Briefly stated, the present invention provides compositions and methods for detecting the *mecA* gene of the methicillin resistant staphylococci.

- Within one aspect of the present invention, methods are provided for determining the presence of an antibiotic resistant *mecA* gene in a biological sample, comprising the steps of (a) treating cells contained within a biological sample to expose target single-stranded nucleic acid molecule, (b) reacting target single-stranded nucleic acids with a scissile link-containing nucleic acid probe which is complementary to a portion of an antibiotic resistant *mecA* gene, and with an enzyme which cleaves double-stranded target-probe complexes, under conditions which allow the target and probe to hybridize to each other to form a double-stranded target-probe complex, the enzyme molecule being capable of cleaving the scissile link of the target-probe complex such that one or more fragments of the nucleic acid probe released from said complex, and (c) determining whether cleaved portions of the nucleic acid probe are produced, and thereby detecting the presence of an antibiotic resistant *mecA* gene. Within various embodiments, determination of whether cleaved probe is produced can be accomplished by directly detecting cleaved portions of the nucleic acid probe, and/or detecting a decrease in the amount of uncleaved probe.

- Within one embodiment, the probe comprises at least a portion of the nucleotide sequence GACGATAATA GCAATACAAT CGCACATACA
30 TTAATAGAGA AAAAGAAAAA AGATGGCAAA GATATTCAAC
TAACTATTGA TGCTAAAGTT CAAAAGAGTA TTTATAAC (SEQ ID NO:13).
Within a further embodiment, the probe consists essentially of at least a portion of the nucleotide sequence GAACTTTAGC ATCAATAGTT AGTTGAATAT
CTTTGCCATC TTTTCTCTTT TTCTCTATTA ATGTATGTGC GATTGTATTG
35 CTATTATCG (SEQ ID NO:4). Other representative probes include: AATAGAGAAA

AAGAAAAAAG ATGGCAAAG (SEQ ID NO:1); and AATAGAGaaaaAGAAAAA
AGATGGCAAAG-3' (SEQ ID NO:5) wherein large letters represent
deoxyribonucleotides and small letters represent ribonucleotides. As utilized herein, a
probe should be at least 8 nucleotides in length, and may be 10, 12, 14, 15, 16, 18, 20, 30
5 or even 100 or more nucleotides in length.

Within various embodiments, the *mecA* gene is from a staphylococcal
species, either coagulase positive (*e.g.*, *S. aureus*), or coagulase negative (*e.g.*, *S.*
epidermidis, *S. sciuri*).

Within other related aspects of the present invention, probes for
10 detecting the present of an antibiotic resistant *mecA* gene in a biological sample are
provided, wherein said probe comprises at least a portion of the sequence
GACGATAATA GCAATACAAT CGCACATACA TTAATAGAGA
AAAAGAAAAA AGATGGCAAA GATATTCAAC TAACTATTGA
TGCTAAAGTT CAAAAGAGTA TTTATAAC (SEQ ID NO:13). Also provided are
15 kits which comprise such probes, along with an enzyme (*e.g.*, RNase H) which cleaves
scissile links.

Within further aspects, kits are provided for detecting the presence of an
antibiotic resistant *mecA* gene in a biological sample, comprising (a) one or more
scissile-link containing nucleic acid probes, and (b) an enzyme capable of cleaving the
20 scissile link when the probe is bound to a target. Within various embodiments, the
enzyme is RNase H. Within further embodiments, the *mecA* gene is from a
staphylococcal species.

These and other aspects of the present invention will become evident
25 upon reference to the following detailed description and attached drawings. In addition,
various references are set forth herein which describe in more detail certain procedures
or compositions (*e.g.*, plasmids, etc.), and are therefore incorporated by reference in
their entirety.

BRIEF DESCRIPTION OF THE DRAWINGS

30 Figure 1 is a schematic illustration of one embodiment of a cycling probe
reaction.

Figure 2 is a histogram showing the frequency distribution results of
screening 285 *Staphylococcus* isolates, including *S. aureus* and *S. epidermidis*, for the
mecA gene from crude lysates using Cycling Probe Technology reaction. The ³²P
35 labeled chimeric probe was mecA945-29 (SEQ ID NO:6) and the reaction mixture

contained the combination of 1.0 mM ethylenebis(oxyethylenitrilo)-tetracetic acid (EGTA) and 2.0 mM spermine. The isolates can be divided into *mecA* positive or *mecA* negative based on the Percent Probe Cut.

Figure 3 is a schematic illustration of the Non-Isotopic CPT Assay. Single-stranded target (I) serves as a catalyst for CPT. In the presence of probe (F-DNA-RNA-DNA-B) (II) and RNase H (III), the RNA portion of the probe-target complex (IV) is cleaved by RNase H. The shorter cleaved probe fragments dissociate from the target thereby regenerating the target DNA for further cycling (V). The anti-fluorescein antibody coupled to horse radish peroxidase (anti-F-HRP) is added (VI) and the reaction is transferred to streptavidin coated plates. The uncut probe bound to anti-F-HRP is captured using the plates (VII). Excess antibody is washed (VIII) and the HRP substrate is added (IX) to measure the amount of uncleaved probe. The absorbance, or color development (X), is inversely proportional to the amount of target DNA.

Figure 4 is a histogram showing the frequency distribution of 120 *S. aureus* clinical isolates based on the detection of the *mecA* gene by Non-isotopic CPT Assay using the fluoresceinated and biotinylated chimeric probe FmecA945-29B (SEQ ID NO:5). The assay was carried out on crude lysates and the isolates can be differentiated into MRSA (*mecA* positive) and MSSA (*mecA* negative) as two non-overlapping populations based on the absorbance value at 650 nm (A_{650}).

Figure 5 is a histogram showing the frequency distribution of 58 *S. aureus* clinical isolates based on the detection of the *mecA* gene by CPT Direct Fluorescence Assay using the fluoresceinated and biotinylated chimeric probe using the plate format. The chimeric probe was FmecA945-29(XL)₄B₃ (SEQ ID NO:5) and the CPT assay was carried out on crude lysates. The isolates can be differentiated into MRSA (*mecA* positive) and MSSA (*mecA* negative) as two non-overlapping populations based on relative fluorescence units (RFU).

Figure 6 is a histogram of the results of fluorescence intensities obtained by CPT Direct Fluorescence Assay from a blind screen of 120 clinical *Staphylococcus aureus* isolates for the *mecA* gene using the single tube format. The chimeric probe was FmecA945-29(XL)₄B₃ (SEQ ID NO:5), the CPT assay was carried out on crude lysates as described in Example 8. These results show that the MRSA and MSSA isolates can easily be differentiated as two non-overlapping populations based on RFU.

Figure 7 is a flow chart for carrying out one embodiment for detecting PCR amplicons by CPT.

Figure 8 shows the results for comparison of CPT-Enzyme immunoassay (CPT-EIA, 8A) and Et-Br stained agarose gel (8B) for the detection of PCR amplicon standard.

Figure 9 shows the comparison of sensitivity of the PCR CPT-EIA (9A) to the Ethidium Bromide stained gels (9B) for the detection of the *mecA* gene from MRSA and MSSA.

Figure 10 shows the results of the effect of PCR cycle numbers on the detection by CPT-EIA (10A) and Ethidium Bromide stained agarose gel (10B) for the detection of the *mecA* gene from MRSA and MSSA.

10 DETAILED DESCRIPTION OF THE INVENTION

DEFINITIONS

"Nucleic acid molecule" refers to a polymeric nucleotide or polynucleotide, which can be of either a natural or synthetic origin. Representative examples of nucleic acid molecules include DNA (ds- or ss-DNA), RNA, DNA-RNA hybrids, or nucleic acid molecules which are composed of or contain a nucleic acid analogues (*e.g.*, α -enantiomeric forms of naturally-occurring nucleotides). Furthermore, nucleotides may be modified in their sugar moieties, or in the pyrimidine or purine base moieties. Examples of modification to sugar moieties include modification or replacement of, for example, one or more hydroxyl groups with another group. Modifications to base moieties include alkyl or acylated pyrimidines and purines. In addition, nucleic acid monomers can be linked by phosphodiester bonds, or analogs of such linkages (*e.g.*, phosphorothioate, phosphorodithioate, phosphoramidite, and the like.).

"Isolated nucleic acid molecule" refers to a nucleic acid molecule that is not integrated into the genomic DNA of an organism. Isolated nucleic acid molecules include, for example, probes and other synthetically or recombinantly generated nucleic acid molecules.

"Scissile linkage" refers to a nucleic acid molecule which is capable of being cleaved or disrupted without cleaving or disrupting any nucleic acid sequence of the molecule itself or of the target nucleic acid sequence. Scissile linkages include any connecting chemical structure which joins two nucleic acid sequences and which is capable of being selectively cleaved without cleavage of the nucleic acid sequences to which it is joined. The scissile linkage may be a single bond or a multiple unit sequence. An example of such a chemical structure is an RNA sequence. Other chemical structures suitable as a scissile linkage are a DNA sequence, an amino acid

sequence, an abasic nucleotide sequence or an abasic nucleotide, or any carbohydrate polymer, *i.e.*, cellulose or starch. When the scissile linkage is a nucleic acid sequence, it differs from the nucleic acid sequences of NA₁ and NA₂ (described below).

5 "Probe Containing a Scissile Linkage" refers to a synthetic nucleic acid molecule which is constructed in view of a known sequence to be complementary or substantially complementary to a target nucleic molecule. Within certain embodiments, the probe comprises the structure [NA₁--S--NA₂]_n wherein NA₁ and NA₂ are different, non-complementary nucleic acid molecules and S is a scissile linkage, and n is an integer from 1 to 10.

10 "Ribonuclease H" ("RNase H") refers to an enzyme capable of specifically cleaving the RNA strand in RNA:DNA hybrid duplex (see generally Crouch & Dirksen in Nucleases, Linn & Roberts (Eds.), pp. 211-241, Cold Spring Harbour Laboratory Press, Plainview, NY, 1982).

15 Thus, as noted above, methods are provided for determining the presence of an antibiotic resistant *mecA* gene in a biological sample, comprising the steps of (a) treating cells contained within a biological sample to expose target single-stranded nucleic acid molecules, (b) reacting the target single-stranded nucleic acids with a scissile link-containing nucleic acid probe which is complementary to a portion of an antibiotic resistant *mecA* gene, and with an enzyme which cleaves double-stranded
20 target-probe complexes, under conditions which allow the target and probe to hybridize to each other to form a double-stranded target-probe complex, the enzyme molecule being capable of cleaving said scissile link of said target-probe complex such that one or more fragments of the nucleic acid probe are released from said complex, and (c) determining whether cleaved portions of the nucleic acid probe are produced, and
25 thereby detecting the presence of an antibiotic resistant *mecA* gene. Utilizing such methods, one of skill in the art can generate accurate and rapid results which can provide same day results from test samples. This allows appropriate utilization of antibiotics for the patients, thereby reducing use of vancomycin. Further more, such methods may be readily utilized to monitor outbreaks or for routine surveillance in both
30 nosocomial and non-nosocomial settings.

Such methods may be utilized to detect the presence of a desired target nucleic acid molecule within a biological sample. Representative examples of biological samples include cultured (*e.g.*, growing a bacteriological medium) or clinical samples, including for example, samples from nasal swabs, blood, urine, stool, abscess
35 or spinal fluids. Methods for generating target nucleic acid molecules may be readily accomplished by one of ordinary skill in the art given the disclosure provided herein

(see generally, Sambrook et al., *Molecular Cloning: A Laboratory Manual* (2d ed.), Cold Spring Harbor Laboratory Press, 1989).

As noted above, within one aspect of the present invention the target nucleic acid molecule is reacted with a complementary single-stranded nucleic acid probe having a scissile linkage. Briefly, a wide variety of nucleic acid probes having scissile linkages may be utilized within the context of the present invention. Preferably, the probe is designed such that, upon cleavage by an enzyme which is capable of specifically cleaving the probe-target complex at the scissile link, probe portions are released which are detectable (see U.S. Patent Nos. 4,876,187, 5,011,769 and 5,403,711).

Preferred probe molecules of the present invention generally have the structure $[(NA_1)_x (-S)_z (-NA_2)_y]_n$ wherein NA_1 and NA_2 are molecules composed of nucleic acids or nucleic acid analogues, $-S-$ is a scissile linkage and x , y , and z are integers from 1-100 and n is an integer from 1-10. Within certain particularly preferred embodiments of the invention, NA_1 and NA_2 may range from 3 to 40 nucleotides, and when S is composed of nucleic acids, may range in size from 2 to 20 nucleotides. In addition, it should be understood that as utilized within the context of the present invention, each of x , y and z can vary with each iteration of n . Although within various embodiments of the invention a single-stranded probe is utilized to react or hybridize to a single-stranded target sequence, the above-described methods should not be limited to only situations wherein complementary probe and target sequences pair to form a duplex.

Single stranded nucleic acid molecules may be obtained and/or prepared directly from a target cell or organism utilizing standard techniques (see, e.g., Sambrook et al., "Molecular Cloning: A Laboratory Manual", Cold Spring Harbor, 1989), or prepared utilizing any of a wide variety of a techniques, including for example, PCR, NASBA, reverse transcription of RNA, SDA, branched-chain DNA and the like.

Within one embodiment, NA_1 and NA_2 as described above are DNA molecules which may or may not have the same sequence. Alternatively, NA_1 and NA_2 may be constructed of RNA molecules, which may or may not have the same sequence, or a combination of RNA and DNA molecules. The DNA or RNA molecules utilized may be derived from naturally occurring sources, or they may be synthetically formed. Each of NA_1 and NA_2 may be from about 5 bases to 10,000 bases in length. Within certain variants, the probe and target nucleic acid molecule need not be perfectly complementary, and indeed, may be purposely different by one, two, three or more nucleic acids (see, e.g., PCT Publication WO 95/14106 and U.S. Patent No. 5,660,988).

Within further variants, the target nucleic acid molecule is present in a heterogeneous population of genomic nucleic acids.

Within other embodiments, NA_1 or NA_2 may be composed of nucleic acid analogues such as methyl phosphonates, carbamates, amidates, triesters, or "Peptide Nucleic Acids" ("PNA"). For example, PNA oligomers can hybridize to complementary target oligonucleotides (DNA or RNA) sequences with very high specificity. Such duplexes are more stable than the corresponding DNA-DNA or DNA-RNA duplexes (Egholm et al., *Nature* 365:556-568, 1993). Furthermore, PNA can bind to double stranded (ds) DNA by strand displacement (Nielsen et al., *Science* 254:1497-1500, 1991) and hence may obviate the traditional double strand denaturation requirement in sample preparation. Low concentration salt is generally preferred for binding of PNA to dsDNA (≤ 50 mM/L of Na^+). Moderate concentration of salt can inhibit binding through double strand displacement of PNA to dsDNA. However, once bound the PNA/DNA duplexes are stable to high concentration of salt. Further, these duplexes are also thermally stable compared to oligonucleotide/oligonucleotide duplexes (duplexes of PNA/DNA are more stable by approximately $1^\circ C$ per base pair compared to corresponding DNA/DNA). Based on the requirement of high sequence specificity to the target oligonucleotide, greater thermal stability and resistance to high salt concentration of the duplex once formed, PNAs are often ideal molecules for use in the methods described herein. Within certain embodiments, two short PNAs may be linked with scissile linkage and used as a highly sequence specific probe.

Probes of the present invention may also have one or more detectable markers attached to one or both ends (e.g., NA_1 or NA_2). The marker may be virtually any molecule or reagent which is capable of being detected, representative examples of which include radioisotopes or radiolabeled molecules, fluorescent molecules, fluorescent antibodies, enzymes, or chemiluminescent catalysts. Within certain embodiments of the invention, the probe may contain one or more labels such as a fluorescent or enzymatic label (e.g., quenched fluorescent pairs, or, a fluorescent label and an enzyme label), or a label and a binding molecule such as biotin (e.g., the probe, either in its cleaved or uncleaved state, may be covalently or non-covalently bound to both a label and a binding molecule (see also, e.g., U.S. Patent No. 5,731,146).

As noted above, the nucleic acid probe has a scissile linkage which is capable of being cleaved or disrupted without cleaving or disrupting any nucleic acid sequence of the molecule itself, or of the target nucleic acid sequence. As used within the context of the present invention, a scissile linkage is any connecting chemical structure which joins two nucleic acid sequences, and which is capable of being

selectively cleaved without cleavage of the nucleic acid sequences to which it is joined. The scissile linkage may be a single bond or a multiple unit sequence. An example of such a chemical structure is an RNA molecule. Other chemical structures which may be suitable as a scissile linkage are DNA molecules, an amino acid sequence, an abasic nucleotide molecule or any carbohydrate polymer (e.g., cellulose or starch). When the scissile linkage is a nucleic acid molecule, it should differ from the nucleic acid sequence of NA_1 and NA_2 .

In the nucleic acid probes described above, when n is greater than one, the unit NA_1 -S- NA_2 repeats. As should be readily understood by one of ordinary skill in the art given the disclosure provided herein, the unit may be the same within each repeat, or may vary randomly in a defined pattern. In addition, the scissile linkage may also vary from unit to unit. For example, one scissile linkage may be an amino acid sequence, and another an RNA molecule.

As noted above, the probes of the present invention may also be linked to a solid support either directly, or through a chemical linker. Representative examples of solid supports include siliceous, cellulosic, polymer-based, or plastic materials.

Within a particularly preferred embodiment of the invention, nucleic acid probes have the structure: $[NA_1 - S - NA_2]_n$ wherein NA_1 and NA_2 are nucleic acid sequences, S is a scissile nucleic acid linkage, and n is an integer from 1 to 10. Within this embodiment, NA_1 and NA_2 are different nucleic acid sequences which are noncomplementary to each other, and $-S-$ is a scissile linkage which is capable of being cleaved or disrupted without cleaving or disrupting NA_1 or NA_2 , or a target nucleic acid sequence capable of hybridizing to the NA_1 or NA_2 sequences, wherein if the scissile linkage is a nucleic acid sequence it is RNA when both NA_1 and NA_2 are DNA sequences, or the scissile linkage is DNA when both NA_1 and NA_2 are RNA sequences.

Methods for constructing such nucleic acid probes may be readily accomplished by one of ordinary skill in the art, given the disclosure provided herein. Particularly preferred methods are described for example by: Matteucci and Caruthers, *J. Am. Chem. Soc.* 103:3185, 1981; Beaucage and Caruthers, *Tetrahedron Lett.* 22:1859-1862, 1981; U.S. Patent Nos. 4,876,187 and 5,011,769; Ogilvie et al., *Proc. Natl. Acad. Sci. USA* 85:8783-8798, 1987; Usman et al., *J. Am. Chem. Soc.* 109:7845-7854, 1987; Wu et al., *Tetrahedron Lett.* 29:4249-4252, 1988; Chaix et al., *Nuc. Acids Res.* 17:7381-7393, 1989; Wu et al., *Nuc. Acids Res.* 17:3501-3517, 1989; McBride and Caruthers, *Tetrahedron Lett.* 24:245-248, 1983; Sinha et al., *Tetrahedron Lett.* 24:5843-5846, 1983; Sinha et al., *Nuc. Acids Res.* 12:4539-4557, 1984; and Gasparutto et al., *Nuc. Acids Res.* 20:5159-5166, 1992.

Particularly preferred probes (and synthetic targets) are based on the *S. aureus mecA* gene described by Song et al., *FEBS Letters* 221: 167-171, 1987 (EMBL Accession No. Y00688). DNA sequences of *mecA* from different MRSA strains show only minor variations (Ryffel et al., *Gene* 94:137-138, 1990, *S. aureus* EMBL Accession No. X52593 and *S. epidermidis* EMBL Accession No. X52592). The *mecA* gene is also distributed among the coagulase-negative Staphylococci and associated with methicillin resistance (cited in Kobayashi et al., *Epidemiol. Infect.* 113:259-266, 1994).

Single probes can be designed to detect the *mecA* gene generally by choosing conserved regions or use of universal bases or abasic sites or other modifications as described in U.S. Provisional application (Attorney's Docket No. 480094.423P2).

Briefly, oligonucleotide synthesis is accomplished in cycles wherein each cycle extends the oligonucleotide by one nucleotide. Each cycle consists of four steps: (1) deprotecting the 5'-terminus of the nucleoside or oligonucleotide on the solid support, (2) coupling the next nucleoside phosphoramidite to the solid phase immobilized nucleotide, (3) capping the small percentage of the 5'-OH groups of the immobilized nucleotides which did not couple to the added phosphoramidite, and (4) oxidizing the oligonucleotide linkage to a phosphotriester linkage.

Representative methods for synthesizing oligonucleotides and biotinylation and fluoresceination of the oligonucleotides are shown in Example 1.

Detection Reactions

As noted above, wide variety of cycling reactions for the detection of a desired target nucleic acid molecule may be readily performed according to the general steps set forth above (*see also*, U.S. Patent Nos. 5,011,769 and 5,403,711).

Within one aspect, such methods generally comprise the steps of (a) treating cells contained within a biological sample to expose target single-stranded nucleic acid molecule, (b) reacting target single-stranded nucleic acids with a scissile link-containing nucleic acid probe which is complementary to a portion of an antibiotic resistant *mecA* gene, and with an enzyme which cleaves double-stranded target-probe complexes, under conditions which allow the target and probe to hybridize to each other to form a double-stranded target-probe complex, the enzyme molecule being capable of cleaving the scissile link of the target-probe complex such that one or more fragments of the nucleic acid probe released from said complex, and (c) determining whether cleaved portions of the nucleic acid probe are produced, and thereby detecting the

presence of an antibiotic *mecA* gene. Within other related aspects, the compositions and methods provided herein may be utilized in a wide variety of other/related methods (e.g., U.S. Patent Nos. 5,210,015; 5,487,972; 5,422,253; 5,691,142; 5,719,028; 5,130,238; 5,409,818; 5,554,517; 5,589,332; 5,399,491; 5,480,784; 5,215,899; 5,169,766; 5,194,370; 5,474,916; 5,698,400; 5,656,430; and PCT publication nos. WO 88/10215; WO 92/08800, , WO 96/02668; WO 97/19193; WO 97/09444; WO 96/21144; WO 92/22671).

Within certain embodiments of the invention, the detection reactions provided herein may be performed utilizing additives such as polyamines (e.g., spermine) or ribosomal proteins which increase sensitivity, specificity, and/or rate of reaction. These, as well as other related aspects are described in U.S. Provisional applications entitled "ADDITIVES FOR USE IN CYCLING PROBE REACTIONS," filed May 18, 1998 (Attorney's Docket No. 480094.419P2); and "METHODS FOR accelerating HYBRIDIZATION OF NUCLEIC ACID MOLECULES," filed May 18, 1998 (Attorney's Docket No. 480094.422P2).

In another embodiment CPT can be used for detecting amplicons generated by any target amplification technology. Example 10 illustrates the use of CPT enzyme immunoassay (CPT-EIA) for the detection of PCR amplicons. CPT allows rapid and accurate detection of PCR amplicons. In addition, CPT adds a second level of amplification but without further amplifying the target, and therefore it is possible to use significantly less number PCR cycles. This will reduce the chance of contamination and false positive. CPT adds a second level of specificity which will prevent detection of non-specific amplicons and primer-dimers. The PCR-CPT method may also be used for mismatch gene detection. Other variations of this assay include 'exponential' cycling reactions such as described in U.S. Patent No. 5,403,711 (see also U.S. Patent No. 5,747,255).

Lateral flow device (strip or dipstick) as described in U.S. Patent Nos. 4855240 and 4703017, for example, represents another embodiment for detection format for the MRSA assay. Instead of detecting uncleaved *mecA* probe on streptavidin coated wells (i.e., EIA format), the uncleaved probe is captured by streptavidin impregnated on a membrane (i.e., strip format). There are several advantage for using this format. There are no additional detection reagents required, less hands-on time, and a short detection time. Representative examples of further suitable assay formats including any of the above assays which are carried out on solid supports such as dipsticks, magnetic beads, and the like (see generally U.S. Patent Nos. 5,639,428; 5,635,362; 5,578,270; 5,547,861; 5,514,785; 5,457,027; 5,399,500; 5,369,036;

5,260,025; 5,208,143; 5,204,061; 5,188,937; 5,166,054; 5,139,934; 5,135,847;
5,093,231; 5,073,340; 4,962,024; 4,920,046; 4,904,583; 4,874,710; 4,865,997;
4,861,728; 4,855,240; and 4,847,194).

5 In another embodiment, CPT can be carried out using the exponential
formats with two sets of nucleic acid probe molecules which are immobilized on solid
support as described in U.S. Patent No. 5,403,711. This would be advantageous since
the assay can be carried out in a single container, the signal can be monitored over time
and would result in a very rapid and sensitive assay.

10 In yet another embodiment CPT-EIA can be used for detecting for
MRSA by use of reverse transcriptase to transcribe cDNA from mRNA expressed by
the *mecA* gene followed by Cycling Probe Technology (RT-CPT) as described in U.S.
Patent NO. 5,403,711. The uncleaved probe specific the cDNA can than be detected by
EIA.

15 The following examples are offered by way of illustration, and not by
way of limitation.

EXAMPLES

EXAMPLE 1

5 CONSTRUCTION OF NUCLEIC ACID PROBES

Nucleic acid molecules can be synthesized utilizing standard chemistries on automated, solid-phase synthesizers such as PerSeptive Biosystems Expedite DNA synthesizer (Boston, MA), PE Applied Biosystems, Inc.'s Model 391 DNA Synthesizer (PCR-MATE EP) or PE Applied Biosystems, Inc.'s Model 394 DNA/RNA Synthesizer
10 (Foster City, CA). Preferably, PerSeptive Biosystems Expedite DNA synthesizer is used and the manufacturer's modified protocol for making oligonucleotides is carried out.

Reagents for synthesis of oligonucleotides are commercially available from a variety of sources including synthesizer manufacturers such as PerSeptive
15 Biosystems, PE Applied Biosystems Inc., Glen Research (Sterling, VA) and Biogenex. For DNA and RNA synthesis, the preferred fluorescein amidite, phosphoramidites of deoxy-and ribo-nucleosides, 2'-O-methyl and reagents, such as activator, Cap A, Cap B, oxidizer, and trityl deblocking reagent are available from PerSeptive Biosystems. Biotin-TEG-phosphoroamidite and Biotin-TEG-CPG are available from Glen Research.
20 Ammonium hydroxide (28%) used for the deprotection of oligonucleotides is purchased from Aldrich. 1 M Tetrabutylammonium fluoride (TBAF) used for removing the 2'-O-tert-butyldimethylsilyl group is purchased from Aldrich and used after drying over molecular sieves for 24 hours. All buffers are prepared from autoclaved water and filtered through 0.2 μ m filter.

25 The following procedure is used for preparing biotinylated and/or fluoresceinated oligonucleotides. Biotin-TEG-CPG (1 μ mol) is packed into a synthesis column. Nucleoside phosphoramidites are then linked to make the defined nucleic acid sequence using PerSeptive Biosystem's modified protocol for making oligonucleotides. Fluorescein-amidite is dissolved in acetonitrile to a final concentration of 0.1 M. The
30 fluorescein amidite is loaded on the synthesizer and added to the 5'- end of the oligonucleotide. Alternatively, phosphoramidite containing thio-linker is added at the 5'- terminal of the chimeric probe using the modified protocol. After the deprotection step described below, the probe is purified by reverse phase HPLC using Millipore's R-2 resin which retains the trityl containing oligonucleotide. In order to generate free
35 reactive thio-group, the HPLC purified probe is treated with silver nitrate for 90 minutes at room temperature followed by neutralization of silver nitrate with dithiotheritol

(DTT). The fluorescein-supernatant is then added to the free thio-group of the probe and then purified either by HPLC or by electrophoresis as described below.

After the synthesis of the oligonucleotide sequence, the resin bound oligonucleotide is treated initially with 25% ethanol-ammonium hydroxide (4 ml) at room temperature for 1 hour and subsequently at 55°C for 16 hours in a closed tube. The tube is cooled, supernatant removed and concentrated to dryness in order to remove ammonia. The residue is dissolved in 1 ml of water and filtered through a 0.2 µm filter. The OD₂₆₀ is determined and an aliquot of approximately 2 OD₂₆₀ units is injected into the R-2 column of Biocad's HPLC to obtain a base line on the chromatogram for the tert-butyldimethylsilyl groups of the chimeric probe.

The remaining probe solution is lyophilized by centrifugal vacuum evaporator (Labconco) in a 1.5 ml microcentrifuge tube. The resulting oligonucleotide residue is deprotected with 1.0 M TBAF for 24 hours. To determine the extent of desilylation which has taken place, an aliquot of the TBAF reaction mixture is injected into the HPLC (R-2 column) using a linear gradient of 0 to 60% acetonitrile in 50 mM triethylammonium acetate (TEAA), pH 6.5. If only a partial desilylation has occurred, the TBAF reaction mixture is allowed to proceed for an additional 12 to 16 hours for complete removal of the protecting groups. The TBAF reaction mixture is quenched with 100 mM NaOAc, pH 5.5 and evaporated to dryness. The crude oligonucleotide product is desalted on a P-6 column (2 cm x 10 cm, Bio-Rad), the fractions are concentrated to approximately 1 ml and the concentration measured at OD₂₆₀.

The crude oligonucleotide is purified by polyacrylamide gel electrophoresis (PAGE) using 20% polyacrylamide-7 M urea. The running gel buffer is 1 x TBE (Tris-Borate- ethylenediamine tetraacetic acid (EDTA), pH 8.3) and the electrophoresis is carried out at 50 mA current for 3.5 to 4 hours. The oligonucleotide band is visualized with UV light, excised, placed in a 15 ml plastic conical tube and extracted by crushing and soaking the gel in 5 ml of 50 mM NaOAc (pH 5.5) for approximately 12 hours. The tubes are then centrifuged at 3000 RPM and the supernatant carefully removed with a Pasteur pipette. The gel is rinsed with 2 ml of the extraction buffer to remove any residual product. The combined extract is concentrated to a volume of approximately 1 ml and desalted on a P-6 column. The fractions containing the probe are pooled and concentrated to a final volume of approximately 2 ml. The analytical purity of oligonucleotides is checked by labeling the 5'- end of oligonucleotide with [γ^{32} P]-ATP and T4-polynucleotide kinase and then running the labeled oligonucleotide on PAGE. OD₂₆₀ is measured using Hewlett Packard's 845X

UV spectrophotometer. The oligonucleotide solution is filtered through a 0.2 μ m filter and stored at -20°C.

Utilizing the above procedure, the following oligomers can be synthesized. In these sequences, upper case letters have been utilized to denote deoxyribonucleotides, lower case letters to denote ribonucleotides, underlined letters to denote 2'-O-methyl linkages, upper case letter F to denote fluorescein label, upper case letter B to denote Biotin, upper case letters XL to denote the XL linker (available from Glen Research or Clontech), and subcase numeral to denote repeats of indicated moiety.

10 mecA945-29D (SEQ ID NO:1)

5'-AAT AGA GAA AAA GAA AAA AGA TGG CAA AG-3'

mecA945T (SEQ ID NO:2)

5'-CTT TGC CAT CTT TTT TCT TTT TCT CTA TT-3'

15

mecA932-59R (SEQ ID NO:3)

5'-cgc aca uac auu aaU aga gaa aaa gaa aaa aga ugg caa aga uau uca acu aac uau ug-3'

ccmecA915-89 (SEQ ID NO:4)

20 5'-GAA CTT TAG CAT CAA TAG TTA GTT GAA TAT CTT TGC CAT CTT TTT
TCT TTT TCT CTA TTA ATG TAT GTG CGA TTG TAT TGC TAT TAT CG-3'

mecA945-29 (SEQ ID NO:5)

5'-AAT AGA GAA AAA Gaa aaA AGA TGG CAA AG-3'

25

mecA945-29A₁₈P (SEQ ID NO:6)

5'-AAT AGA GAA AAA Gaa aaA AGA TGG CAA AGA₁₈-3'

mecA945-29(2' OMe) (SEQ ID NO:7)

30 5'-AAT AGA GAA AAA Gaa aaA AGA TGG CAA AG-3'

mecA945-29R (SEQ ID NO:8)

5'- aau aga gaa aaa gaa aaa aga ugg caa ag-3'

mecA834-25 (SEQ ID NO:9)

5 5'-TGG TAA AAA GGG ACT CGA AAA ACT T-3'

mecAL1039-22 (SEQ ID NO:10)

5'-GGT GGA TAG CAG TAC CTG AGC C-3'

10 mecA869-29 (SEQ ID NO:11)

5'-AGC TCC AAC ATG AAG ATG GCT ATC GTG TC-3'

mecAL1042-30 (SEQ ID NO:12)

5'-ACC TGT TTG AGG GTG GAT AGC AGT ACC TGA-3'

15

FmecA945-29B (SEQ ID NO:5)

5'-FAAT AGA GAA AAA Gaa aaA AGA TGG CAA AGB-3'

F-mecA945-29(XL)4B3 (SEQ ID NO:5)

20 5'-FAAT AGA GAA AAA Gaa aaA AGA TGG CAA AG(XL)₄B₃-3'

mecA913-1020 (SEQ ID NO:13)

5'-GACGATAA TAGCAATACA ATCGCACATA CATTAATAGA GAAAAAGAAA
AAAGATGGCA AAGATATTCA ACTAACTATT GATGCTAAAG

25 TTCAAAAGAG TATTTATAAC-3'

mecA938-36 (SEQ ID NO:14)

5'-ATACATTAATAGAGAAAAAGAAAAAAGATGGCAAAG-3'

30 mecA938-36 (SEQ ID NO:15)

5'-ATACATTAATAGAGaaaaAGAAAAAAGATGGCAAAG-3'

Table of other *mecA* probes

Probe name	Sequence ID No.	Sequence 5' to 3'
mecAL53-22	SEQ ID NO:16	ACGGAGAAgaagTTGTAGCAGG
mecA172-27	SEQ ID NO:17	GGTGAAGTAgaagTGACTGAACGTCCG
mecA356-25	SEQ ID NO:18	AAGATGGTATGTggaaGTTAGATTG
mecA358-24	SEQ ID NO:19	GATGGTATGTggaaGTTAGATTGG
mecA360-26	SEQ ID NO:20	TGGTATGTGgaagTTAGATTGGGATC
mecA824-27	SEQ ID NO:21	ATGCAGTTATTGGTaaaaAGGGACTCG
mecAL1255-23	SEQ ID NO:22	TGTTTGagggTGGATAGCAGTAC
mecA1393-25	SEQ ID NO:23	GAUAACAUUUucuuUGCUGAGAGUAG 2'OMethyl, except for the ribonucleotides
mecA1735-28	SEQ ID NO:24	CAAGTCGTAAATaaaaCACATAAAGAAG
mecA1913-25	SEQ ID NO:25	TACAAGATAAAggaaTGGCTAGCTA
mecA1930-27	SEQ ID NO:26	GCTAGCTACAATGCCaaaaTCTCAGGT

5

EXAMPLE 2

ISOTOPIC CYCLING PROBE TECHNOLOGY REACTION

Cycling probe technology (CPT) reaction and conditions are performed utilizing modified procedures from previously published methods (WO 95/14106; Bekkaoui et al., *BioTechniques* 20(2): 240-248, 1996). Briefly, a specified chimeric probe is 5' labeled with radioactive ^{32}P using [^{32}P]-ATP (Du Pont, Sambrook et al., 1990) and T4 polynucleotide kinase (RTG; Pharmacia Biotech, Piscataway, NJ). A single tube of RTG is resuspended in 15 μl of water. One pmol of probe is combined with 5 μl of γ - ^{32}P ATP and 3 μl of RTG. The final volume is adjusted to 10 μl with water and incubated at 37°C for 30 minutes. The unincorporated γ - ^{32}P ATP is separated from the kinased probe by using a G50 Nick column (Pharmacia). The recovered probe is adjusted to 0.1 x in SSC buffer (15 mM NaCl, 1.5 mM sodium citrate, pH 7.0) and stored at -20°C.

Unless otherwise indicated, the CPT reaction is carried out by adding in order, the following: TES cycling buffer, chimeric labeled probe, RNase H to give a cycling cocktail, which is then added to the denatured sample to be tested. The cycling reaction mixture contains the specified concentrations of chimeric probe, nucleic acid either as purified genomic DNA or crude lysate target, 3.3 μg RNase H in TES cycling buffer (TES-CB) which has the following final concentration: 0.05% Triton X-100®, 4 mM MgCl_2 , 1 mM ethylenedis(oxyethylenitrilo)-tetracetic acid (EGTA), 20 mM TES

buffer, pH 6.8. Sample preparations, addition of test additives, and other components used in the cycling reactions are described in the specific examples.

Unless otherwise specified, the CPT reactions are incubated for 30 minutes at 56°C and then stopped by addition of urea loading buffer (8 M urea, 100 mM ethylenediamine tetracetic acid (EDTA) and 0.25% each of blue bromophenol and xylene cyanol, 80 mM phosphate buffer) at 56° C. The reaction mixtures are then resolved by 7 M urea-20% acrylamide/bisacrylamide (19:1) gel electrophoresis (SDS-PAGE) at 500 Volts, with cooling. The gel is analyzed on a PhosphorImager™ utilizing ImageQuant™ software (Molecular Dynamics, Sunnyvale, CA). The amount of cycled probe is estimated by integration of the areas of bands corresponding to intact and cleaved probe.

Unless otherwise stated, in a CPT reaction Percent Probe Cut is the total amount of cut probe relative to the total amount of the input probe (Equation No. 1):

$$\text{Percent Probe Cut} = (\text{Probe Cut} / \text{Total input probe}) \times 100 \quad (1)$$

In a simple CPT system, the C1 background refers to the Percent Probe Cut in the reaction buffer without RNase H or homologous target present. C2 refers to Percent Probe Cut in the presence of RNase H but without homologous target (Equation No. 2):

$$C2 = (\text{Probe cut} / \text{Total input probe}) \times 100 \quad (2)$$

For complex CPT system, C3 refers to Percent Probe Cut in the sample (biological samples that contains extraneous components, such as heterologous DNA or proteins) in the absence of RNase H. C4 refers to Percent Probe Cut in the biological sample in the presence of RNase H, but in the absence of homologous target (Equation No. 3):

$$C4 = (\text{Probe cut} / \text{Total input probe}) \times 100 \quad (3)$$

Net Percent Probe Cut is the percent of probe cut due to homologous target and is calculated by subtracting the background C2 (simple system), or C4 (complex system) from the Percent Cut (Equations No. 4 or 5, respectively).

$$\text{Net Percent Probe Cut} = \text{Percent Cut} - C2 \quad (4)$$

$$\text{Net Percent Probe Cut} = \text{Percent Cut} - C4 \quad (5)$$

Signal to noise ratio (S:N) for CPT is defined as the ratio of the Percent Probe Cut in the presence of the homologous target to the C2 (simple system, Equation No. 6) or C4 (complex system, Equation No. 7):

$$S:N = \text{Percent Cut} / C2 \quad (6)$$

$$S:N = \text{Percent Cut} / C4 \quad (7)$$

EXAMPLE 3

PREPARATION OF THERMOSTABLE RNASE H

The following example describes one representative method for
5 preparing thermostable RNase H from *Thermus thermophilus*.

The cloning of the thermostable gene and its expression is described in detail in WO 95/05480 and Bekkaoui et al., *BioTechniques* 20:240-248, 1996 based on the modification of the method by Kanaya & Itaya, *J. Biol. Chem.* 267:10184-10192, 1992. Briefly, the *T. thermophilus* RNase H gene (Kanaya & Itaya, *Supra*) is cloned by
10 PCR into vector pT7-7 (pIDB9) and is subcloned into the vector pET11a (Novagen) resulting in the plasmid pIDB33. Plasmid pIDB33 is subsequently transformed into the bacterial strain BL21(DE3) (Novagen, Madison, WI). BL21(DE3) cells containing pIDB33 are grown at 37°C in LB medium (Sambrook et al, 1990) containing 0.1 mg/ml ampicillin. When the culture is at an OD₆₀₀ of 0.6 - 0.8, IPTG is added to a final
15 concentration of 0.5 mM and the cells are cultured for four more hours. RNase H is expressed in the inclusion bodies with the pIDB33 construct.

Cells are harvested by centrifugation at 3000x g for 15 minutes at 4°C. Cell pellets are resuspended at 1 g fresh weight in 5 ml of TE buffer (10 mM Tris, pH 7.4, 1 mM EDTA buffer). The cells are lysed in a dry ice/ethanol bath using a sonicator
20 (Branson, model 450) and centrifuged at 15,000x g for 30 minutes at 4°C. The pellet is resuspended in 7 M urea in TE buffer, pH 8.0 and incubated with stirring for 2 hours at 4°C. The resuspended cells are sonicated for 2 minutes on ice, followed by centrifugation at 12,000x g for 10 minutes and the supernatant is collected and dialyzed overnight against 1 l of urea sodium acetate buffer (8 M urea, 20 mM sodium acetate,
25 pH 5.5) with two changes. After a centrifugation for 20 minutes at 31,000x g, the clear protein supernatant solution (150 ml) is collected and mixed with approximately 25 ml of pre-swollen phosphocellulose (equilibrated 2 x in column buffer, P11, Whatman International Ltd., Kent, UK) for 3 hours. The resulting slurry is washed twice with the urea sodium acetate buffer and poured into a column. The column is connected to an
30 FPLC system (Pharmacia) and step washed twice with 140 mM and 210 mM NaCl in the urea sodium acetate buffer. The protein is then eluted using a 0.21 to 0.7 M NaCl linear gradient in the urea sodium acetate buffer. At the end of the salt gradient, the column is maintained at 0.7 M NaCl until all the protein is eluted. Fractions are analyzed by SDS-PAGE and those containing RNase H are pooled and desalted using a
35 Sephadex G-25 column with buffer containing 150 mM NaCl in 20 mM sodium acetate, pH 5.5. The eluted protein fractions are pooled, concentrated with a Centriprep 10 filter

(Amicon, Beverly, MA), and stored at -20°C in glycerol storage buffer (40% glycerol, 150 mM NaCl and 20 mM sodium acetate, pH 5.5).

5

EXAMPLE 4

DETERMINING METHICILLIN RESISTANCE STATUS OF *STAPHYLOCOCCUS AUREUS* BY DETECTION OF *MECA* GENE USING CPT REACTION

10 The following example demonstrates the utility of chimeric probe mecA945-29 (SEQ ID NO:5) and the effectiveness of spermine and EGTA in CPT reaction for the detection of the *mecA* gene from crude lysates of *S. aureus* isolates.

This experiment was designed to examine the effect of spermine and EGTA in the CPT reaction for detection of the *mecA* gene in MRSA isolates using crude lysates.

15

For this experiment the MRSA (ATCC 33592, American Type Culture Collection, Rockville, MD) and MSSA (ATCC 11632) isolates were grown on trypticase soy agar (TSA) plates with 5% sheep blood (PML Microbiologics, Richmond, BC) at 37°C overnight. A sterile swab was used to remove the colonies from the TSA plate followed by resuspension of the cells in 2 ml of 0.05% Triton X-100® in 20 mM TES buffer (pH 6.8). The cell suspensions were then adjusted to McFarland #5 standard cell density (approximately 1.5×10^9 cells/ml). Fifty µl of the cell suspensions (approximately 7.5×10^7 cells) were then transferred to microcentrifuge tubes. Lysis of the cells was carried out with the addition of achromopeptidase (Wako Bioproducts, Richmond, VA) to a final concentration of 150 units/ml per sample. The suspensions were mixed and incubated at 37°C for 20 minutes.

25 The chimeric probe mecA945-29 was synthesized and labeled as described in Examples 1 and 2. Thermostable RNase H was produced as described in Example 3. CPT reactions and analysis were carried out as in Example 2 except for the following: 1.8 fmol mecA945-29 chimeric probe was used and the additive concentrations tested were 1 mM EGTA, 2 mM spermine or a combination of 1 mM EGTA and 2 mM spermine. Fifty µl of crude lysates samples were heat denatured in a heating block at 95°C for 5 minutes, and then directly transferred to a 58°C water bath (reaction temperature was 56°C). The reaction cocktail (50 µl) was immediately added and the incubation was continued for an additional 20 minutes. At the end of incubation, an equal volume of loading dye containing 40 mM PB (100 µl) was added

30
35

to the samples in the water bath. The samples were then transferred to a 95°C heating block for 5 minutes. Samples were spun down briefly and 20 µl was loaded onto an acrylamide gel for electrophoresis.

Table 1 summarizes the results of the effect of spermine and EGTA in CPT reactions for detection of the *mecA* gene from MRSA lysates. Briefly, it was observed that in the absence of spermine or EGTA there was no differentiation between the MRSA and MSSA isolates due to the high C4 background. The addition of EGTA alone reduced the Percent Probe Cut in both MRSA and MSSA, but still did not permit the differentiation between the two. Addition of spermine alone to the CPT reaction permitted the detection of MRSA by lowering C4 background, which resulted in a signal to noise ratio of approximately 5. Addition of both EGTA and spermine into the CPT reaction dramatically improved detection of the target. As shown in Table 1, there was a major reduction in the C4 background and *mecA* MRSA could be detected with an impressive signal to noise ratio of 20. These results clearly indicate the necessity of adding both spermine and EGTA to the cycling reaction in order to obtain clear differentiation between MRSA and MSSA isolates.

Table 1. The effect of spermine and EGTA in CPT reactions for detection of *mecA* gene from crude lysates of MRSA.

EGTA (mM)	Spermine (mM)	C4 (MSSA) Background (%)	MRSA Probe Cut (%)	MRSA Net Probe Cut (%)	S:N
-	-	84	77	0	-
1	-	21	22	1	1.0
-	2	15	71	56	4.8
1	2	2.5	51	48	20.0

The above example demonstrates the successful use of isotopically labeled chimeric *mecA*945-29 probe for differentiating MRSA from MSSA by the detection of *mecA* gene in the presence of the additives spermine and EGTA.

EXAMPLE 5

CLINICAL SCREENING FOR METHICILLIN RESISTANT STAPHYLOCOCCAL ISOLATES BY DETECTION OF THE *mecA* GENE USING CPT REACTION

5 The following example demonstrates the successful use of isotopically labeled chimeric probe and the additives, spermine and EGTA, in CPT reactions for the detection of *mecA* gene from crude lysates of staphylococcal clinical isolates.

 This experiment examines the use of ³²P labeled chimeric probe *mecA*945-29 (SEQ ID NO: 5) and the combination of spermine (2.0 mM) and EGTA
10 (1.0 mM) in CPT reaction for the detection of the *mecA* gene from crude lysates of 285 staphylococcal isolates. These isolates were from the following sources: Wishart Memorial Hospital (Indianapolis, IN), Cleveland Clinic Foundation (Cleveland, Ohio), Vancouver General Hospital (Vancouver, BC) and 25 reference strains. In total there were 238 *S. aureus* and 47 *S. epidermidis* isolates.

15 The crude lysate preparations, probe synthesis, CPT procedure and analyses were carried out as described in Example 4 except that the cells were picked from the TSA blood plate with a 1 µl plastic loop (PML Microbiological, Richmond, BC, Canada) resuspended in 50 µl of 0.05% Triton X-100® in 20 mM TES buffer (pH 6.8) and lysed with the addition of achromopeptidase (Wako Bioproducts) as described
20 in Example 4. The DNA was heat denatured at 95° C for 5 minutes prior to use. The experiment was carried out as an operator blind study. The isolates were also tested with conventional oxacillin screening agar (PML Microbiological), Kirby-Bauer Disc diffusion, minimal inhibitory concentration (MIC) using E-Test with 4 % NaCl Mueller-Hinton and *S. aureus* were tested with the BBL® Crystal™ MRSA ID test
25 (Beckton Dickinson).

 When CPT reaction results were compared to oxacillin agar screening, 4 discrepant samples were found. These isolates were observed to be agar screen positive but CPT negative. After discrepant resolution by PCR (Example 7) it was confirmed
30 that the *mecA* gene was absent in these isolates. The results of the above experiment are depicted in Figure 2 as a frequency distribution histogram of the number of isolates versus Percent Probe Cut. Briefly, the frequency distribution of Percent Probe Cut separated the isolates into two distinct populations based on presence or absence of *mecA* gene using operator blind study.

 Each of the susceptibility tests employed in this study failed to correctly
35 identify several isolates of staphylococci. The gold standard oxacillin agar screen identified 4 *S. aureus* isolates as MRSA, although the *mecA* gene was shown not to be

present. Each of these four isolates displayed borderline resistance to oxacillin (MIC's 3-16 ug/ml) and were likewise misidentified by MIC E test and oxacillin disk diffusion. One of these four isolates was further misidentified by the BBL Crystal ID MRSA System. An additional 31 *S. aureus* isolates lacking the *mecA* gene were designated as
 5 MRSA by the E test with oxacillin MIC's 3-12 ug/ml and two of these isolates were also missed by oxacillin disk diffusion. Each of these borderline oxacillin resistant *S. aureus* (BORSA) isolates were further shown to be susceptible to oxacillin in the presence of clavulanic acid by disk diffusion.

Conventional susceptibility tests cannot reliably differentiate between
 10 oxacillin borderline-susceptible *S. aureus* isolates and heterogeneously resistant MRSA isolates with low MIC.

Table 2. Isolates incorrectly identified by susceptibility tests

	Isolates		
	BORSA	MRSA	MRSE ¹
Total Isolates Tested	35	127	46
MIC E-Test	35	0	4
Oxacillin Agar Screen	4	0	0
Crystal MRSA ID	1	4	Not Done
Oxacillin Disc Diffusion	6	4	2

¹MRSE refers to methicillin resistant *Staphylococcus epidermidis*

15 The CPT assay accurately detected the *mecA* gene in *S. aureus* and *S. epidermidis* isolates and allowed for the correct identification of methicillin resistant staphylococci from methicillin susceptible staphylococci. This assay was also able to differentiate the *mecA* positive MRSA from BORSA, which does not contain the *mecA* gene.

20 The above example demonstrates the sensitivity and specificity of the isotopically labeled *mecA*945-29 probe for the *mecA* gene from crude lysates of both coagulase positive and negative staphylococcal clinical isolates.

EXAMPLE 6

25 PCR DETECTION OF *MECA* GENE

PCR for discrepant analysis is carried out by the following method.

Oligonucleotide primer pair *mecA*834-25 and *mecA*1039-22 (SEQ ID NOs:9 and 10), specific for the *mecA* sequence of MRSA, were synthesized as described in Example 1. Crude lysates of MRSA and MSSA ATCC isolates were used as controls and PCR was performed after the hot start with the Taq polymerase.

Hot-start PCR was carried out in a 50 μ l volume by adding the Taq polymerase at 80°C after denaturation for 5 minutes at 95°C. The final PCR reaction mixture contained the following: 200 μ M of each dNTP mix (dATP, dGTP, dCTP, dTTP, Pharmacia), 1.5 mM of MgCl₂, 50 mM KCl, 20 mM Tris HCl, pH 8.4, (1x PCR buffer, Gibco-BRL), 0.5 μ M of each primer pair, 1U of Taq DNA polymerase (Gibco-BRL) and 2 ng of *Staphylococcus* DNA crude lysate sample in a final reaction volume of 50 μ l. Samples were cycled in the thermal cycler (PTC 100, MJ Research Inc.) using a cycle of 94°C for 40 seconds, 53°C for 40 seconds and 72°C for 90 seconds. Amplification is carried out for 50 cycles.

After amplification the samples were analyzed electrophoretically using 1.8% agarose gel containing 0.5 μ g/ml of ethidium bromide. A molecular weight marker was also included. The sample was considered to be positive if the 227 bp amplicon was detected. This amplicon was detected in the ATCC MRSA control but not in the ATCC MSSA control or any of the discrepant *S. aureus* isolates.

EXAMPLE 7

NON-ISOTOPIC MRSA ASSAY

The following example demonstrates a rapid non-isotopic CPT assay for the detection of *mecA* gene in clinical isolates of *S. aureus*.

The non-isotopic MRSA Assay which combines CPT with an enzyme immunoassay (CPT-EIA) is schematically illustrated in Figure 3. This Rapid MRSA Test uses a fluoresceinated and biotinylated chimeric probe which provides an RNase H sensitive scissile linkage when bound to the complementary base sequence of the *mecA* gene. The uncleaved probe (*mecA* negative) is detected by binding of the probe to a solid surface and attachment of an antibody conjugated with horse radish peroxidase, which converts a substrate to a colored end product. Cleavage of the probe (*mecA* positive) prevents binding of the probe-antibody complex to the solid surface thus preventing formation of the colored end product. A result is generated in 90 minutes.

This experiment examines the use of fluorescein labeled chimeric probe F*mecA*945-29B (SEQ ID NO: 5) and the combination of spermine and EGTA in CPT reaction for the detection of the *mecA* gene from crude lysates of 102 staphylococcal

isolates. The source of *S. aureus* isolates were from the following: Wishard Memorial Hospital, Cleveland Clinic Foundation, Vancouver General Hospital and ATCC. In total there were 51 MRSA and 51 MSSA isolates.

Effective lysis of both MRSA and MSSA were developed and optimized.

- 5 The composition of the Lysis Reagent is as follows: 200 Units/ml of achromopeptidase (Wako Bioproducts, Wako), 0.02 mg/ml lysostaphin (Sigma, St. Louis, MO), 0.05% (v/v) Triton X 100® and 20 mM TES buffer, pH 8.5.

- The chimeric probe FmecA945-29B was synthesized, fluoresceinated and biotinylated as described in Example 1. The purified thermostable RNase H was prepared as described in Example 3. The isolates were grown as described in Example 4 and 1 µl loopful of culture growth was placed in 1.5 ml microcentrifuge tube containing 50 µL of the Lysis Reagent. The samples were incubated at 54°C or room temperature for 10 minutes. DNA was denatured at 95°C for 2 minutes prior to CPT reaction. The optimized CPT reaction reagents for the subtractive assay were as follows: 20
15 fmol/reaction of FmecA945-29B, 50 µl of crude lysate, 0.05% Triton X 100®, 2 mM MgCl₂, 25 µM EDTA, 625 µM spermine, 1.65 µg/reaction of RNase H, 20 mM TES, pH 6.8, in final reaction volume of 100 µl. The controls used were *mecA* positive *S. aureus* (ATCC 33592) and *mecA* negative *S. aureus* (ATCC 11632). CPT reaction was carried out at 54°C for 25 minutes.

- 20 After cycling, 100 µl of Binding Reagent (Peroxidase Stabilizing Buffer, DAKO, Mississauga, ON), sheep polyclonal anti-fluorescein-horse radish peroxidase conjugated antibody (1/750 dilution, NEN, Boston, MA) was added to the tubes. Detection was carried out using streptavidin coated strip wells (Boehringer Mannheim GmbH, Germany, Boeringer). The CPT reaction was transferred to streptavidin coated
25 strip well, mixed for 10 seconds and incubated for 10 minutes at room temperature. The liquid was discarded and washed twice with 300 µl of Wash Buffer (137 mM NaCl, 2.7 mM KCl, 1.8 mM KH₂PO₄, 10.1 mM Na₂HPO₄, 0.5% Tween 20, pH of 7.3). This was followed by addition of 200 µl of substrate (Tetramethylbenzidine/H₂O₂, Sigma) and allowed to develop for 3 minutes at room temperature. The development was
30 stopped using 100 µl of Detection Stop Reagent (750 mM Tris, 1.5% (w/v) sodium dodecyl sulfate, pH of 7.7). The plate is read using a Vmax plate reader (Molecular Devices) set at OD of 650 nm (OD₆₅₀).

Table 3 and Figure 4 summarize the results of the screen for the *mecA* gene of MRSA by using the subtractive CPT assay.

Table 3. The mean and standard deviations (SD) of absorbance at 650 nm (A_{650}) from the experiment examining the detection of MRSA (n=51) and MSSA (n=51) clinical isolate lysates using the subtractive CPT assays.

	MRSA	MSSA
n	51	51
$A_{650 \text{ nm}}$ Mean	0.053	0.239
Standard Deviation	0.004	0.024
Mean - 3x SD	0.040	0.166
Mean + 3x SD	0.066	0.314

5 The results indicate that all 51 MRSA or MSSA data points lie within 3 standard deviations (SD) of their corresponding means. Therefore no overlap exists between the MRSA mean plus 3x SD and the MSSA mean minus 3x SD. This allowed for an unambiguous test results which separates the MRSA population from the MSSA population.

10 The above example demonstrates that the chimeric fluoresceinated and biotinylated mecA945-29 probe can successfully be used in a non-isotopic CPT-EIA for differentiating MRSA from MSSA by detecting the *mecA* gene.

15

EXAMPLE 8

MRSA TEST: FORMAT, REAGENT AND KIT COMPOSITION

The following is one representative example of a kit for detecting the *mecA* gene from MRSA.

20 This kit allows for rapid detection of MRSA by detecting the *mecA* gene using the non-isotopic CPT assay (CPT-EIA) and has been optimized to detect MRSA isolates (discrepant) that are hard to lyse or those that produce nucleases.

The Rapid MRSA Test Kit (48 tests) is composed of the following items:

- 25 * MRSA Lysis Reagent (2)
- * Streptavidin Coated Microwells (48)

- * MRSA Cycle Reagent (48)
- * Wash Buffer (1 X 50 mL)
- * MRSA Lysis Reconstitution Buffer (1 X 3 mL)
- * Detection Substrate Reagent (1 X 12 mL)
- 5 * Cycle Reconstitution Buffer (1 X 6 mL)
- * Detection Stop Reagent (1 X 5.5 mL)
- * MRSA Cycle Stop Reagent (1 X 6.8 mL)
- * Transfer Pipette (50)
- * 50 μ L Dropstirâ (75)
- 10 * 50 μ L Dropstirâ (75)
- * 200 μ L Dropstir (50)
- * 200 μ L Dropstir (50)

15 The following describes the composition, reagents and materials that form part of the kit:

- * MRSA Lysis Reconstitution Buffer: Water and 20 ppm ProClin 300™ (Sigma).
- * MRSA Lysis Reagent (lyophilized): TES, Triton X-100®, Trehalose (Sigma), Achromopeptidase (Wako) and EGTA
- 20 * Cycle Reconstitution Buffer: 4 mM MgCl₂ and 20 ppm ProClin 300™.
- * MRSA Cycle Reagent (lyophilized): Trehalose, Polyvinylpyrrolidone, TES, Triton X-100®, spermine, *mecA* probe, RNase H and bovine serum albumin.
- 25 * MRSA Cycle Stop Reagent: Buffered Salt Solution (DAKO) containing anti-fluorescein antibody conjugated with horse radish peroxidase (1/1000 final dilution).
- * Streptavidin Coated Microwell (Boehringer).
- 30 * Wash Buffer: 137 mM NaCl, 2.7 mM KCl, 1.8 mM KH₂PO₄, 10.1 mM Na₂HPO₄, 0.5% Tween 20 and 20 ppm ProClin 300.
- * Detection Substrate Reagent: Tetramethylbenzidine (Sigma) and H₂O₂.

- * Detection Stop Reagent: 0.75 mM Tris and 1.5% Sodium dodecyl sulfate.

The procedure for carrying out the assay for detecting the *mecA* gene from the crude lysates of *S. aureus* is as follows:

5 A. Reconstitution of MRSA Lysis Reagent:

1. To a vial of MRSA Lysis Reagent pipette 1.5 mL of MRSA Lysis Reconstitution Buffer.
2. Swirl to dissolve.
3. Let sit at room temperature for 2 to 3 minutes before use.
- 10 4. Once reconstituted a vial of MRSA Lysis Reagent can be used for 2 weeks when stored at 2°-8°C.

 B Reconstitution of MRSA Cycle Reagent

1. The reconstitution should be performed during the incubation steps of Specimen Preparation.
- 15 2. To a vial of MRSA Cycle Reagent add 2 drops of the Cycle Reconstitution Buffer.
3. Swirl to dissolve.
4. This is a single use reagent. This reagent must be used within 30 minutes of reconstitution.

20 C Sample Preparation

1. Using a 50 µL Dropstir add one drop of the reconstituted MRSA Lysis Reagent to each 1.5 mL microcentrifuge tube. (one tube per sample)
- 25 2. Add 1 µL loop of growth from an 18 to 24 hour culture on a tryptic soy agar plate containing 5% sheep blood. Mix well to completely suspend cell growth.
3. Place at 55°C for 20 minutes.
4. Place at 95°C for 5 minutes.

 D Cycling Probe Technology

- 30 1. Transfer tubes with lysate to 55°C.

2. Using a 50 μ L Dropstir add one drop of the reconstituted MRSA Cycle Reagent to each tube.
3. Incubate at 55°C for 25 minutes.
4. Add 3 drops of MRSA Cycle Stop Reagent, with tubes at 55°C.

5 E Detection

1. Place the necessary number of Streptavidin Coated Microwells (one Microwell per sample) into the Microwell frame.
2. Transfer the entire cycle reaction to Streptavidin Coated Microwell using a transfer pipette.
- 10 3. Incubate at room temperature for 10 minutes.
4. Invert Streptavidin Coated Microwell to discard liquid.
5. Fill each Streptavidin Coated Microwell completely with Wash Buffer.
6. Invert Streptavidin Coated Microwell to discard liquid.
- 15 7. Tap each Streptavidin Coated Microwell 5 times on dry paper towel.
8. Repeat steps 5 - 7.
9. Using a 200 μ L Dropstir add one drop of Detection Substrate Reagent to each of the Streptavidin Coated Microwells.
- 20 10. Place at room temperature for 5 minutes.
11. Add 4 drops of Detection Stop Reagent to each Streptavidin Coated Microwell.
12. Mix for 10 seconds.
13. Incubate at room temperature for 3 minutes.
- 25 14. Within 30 minutes visually read and record the color zone or measure/record the OD₆₅₀.

EXAMPLE 9

DIRECT FLUORESCENCE CPT ASSAY FOR *MECA* MRSA

30

The following example demonstrates the use of a direct fluorescence assay for the detection of the *mecA* gene in MRSA isolates by CPT using crude lysates.

Two experiments were carried out for the detection of the *mecA* gene from clinical isolates using the direct fluorescence assay (DFA) combined with CPT (CPT-DFA). In the first experiment, 58 isolates were screened using a plate reader format, and in the second experiment, 120 isolates were screened using single tube reader format. Briefly, the assay uses a fluoresceinated and biotinylated chimeric probe complementary to a sequence within the *mecA* gene present in MRSA, but not in MSSA. The probe is labeled with fluorescein at the 5' end and biotin at the 3' end. The CPT assay is performed with crude lysate preparations from *Staphylococcal* cells in the presence of RNase H and the chimeric probe. After the cycling reaction, streptavidin coated magnetic beads are added to bind the uncleaved probe. The supernatant containing the cleaved fragment labeled with fluorescein is separated from the beads using a magnet and the supernatant is transferred to a glass tube or a microtiter plate for fluorescence measurement.

A. Source of Clinical isolates and Sample preparation

The source of the fifty-eight clinical isolates were obtained from Cleveland Hospital, Wishard Memorial and Vancouver General Hospital. All MRSA and MSSA cells were prepared and lysed essentially as described in Example 4 except that the lysates were prepared as either 2x McFarland No. 5 standard density or 1 μ l loop of cells in 50 μ l volume. One μ l loop of cells is approximately equivalent to 5x McFarland No. 5 standard.

B. Binding of biotinylated probes using streptavidin coated magnetic beads

The streptavidin coated magnetic beads (Dynal M-280, Oslo, Norway) were prepared by washing two times in an equal volume of TES cycling buffer (4 mM $MgCl_2$, 0.05% Triton X-100®, 20 mM TES, pH 6.8). The beads were then re-suspended in 10 times the original volume with cycling buffer containing NaCl. The diluted beads were added to the reactions containing biotinylated probe to a final concentration of 50 μ g of beads/reaction and a final NaCl concentration of 1.5 M. Binding was carried out in a thermomixer (Eppendorf) at 37 °C with mixing at a speed of 13 x 100 minutes⁻¹, for 10 minutes. The supernatant was then separated from the beads using an MPC magnet (Dynal).

C. Fluorescence detection of probe after binding

Probe was detected after binding using the Fluoroskan fluorescence plate reader (Labsystems, Needham, MA) by placing the supernatant containing the cleaved

probe in a well of MicroFluor 'U' black round bottom plate (Dynatech, Chantilly, VA). To each well containing a sample, 150 µl of 0.22 M DEA pH 10 was added. Any bubbles in the wells were removed using the edge of a Kimwipe (Roswell, GA). The plate was scanned in the plate reader with an excitation wavelength of 485 nm, an
5 emission wavelength of 538 nm and a scan/well time of 20 x 0.1 sec, at room temperature. Similar detection using the Beacon-2000 tube reader (Panvera, Madison, Wisconsin) was performed, by placing the supernatant containing the probe in a borosilicate glass tube (Kimble, Toledo, OH), that contains 11 µl of 2.0 M DEA, pH 10. The samples were then vortexed and the fluorescence intensity was measured using the
10 static mode of the Beacon-2000 instrument. The excitation and emission wavelengths were 485 nm and 515 nm respectively and an average of 10 read cycles at 25°C was used.

D. CPT procedure with crude lysates of MRSA or MSSA

The assay used a chimeric probe FmecA945-29(XL)₄B₃ (SEQ ID NO:5) labeled with fluorescein at the 5' end and three biotin at the 3' end. Cycling reactions
15 with crude lysate were performed in a 50 µl reaction containing 25 µl of crude lysates. The lysates were denatured at 95°C for 2 minutes. CPT reaction was carried out and the final conditions were as follows: 1 pmol chimeric probe, 25 µl of crude lysates, 50 µM EDTA, 0.5 mM spermine, 1.5 µg of RNase H in a final reaction volume of 50 µl. All
20 reactions were cycled in a 60°C water bath, in microcentrifuge tubes (uncapped) for 50 minutes. Reactions were stopped with the addition of an equal volume of diluted beads (50 µg of beads / reaction in Cycling Buffer and NaCl), while still in the water bath. Binding and detection were carried out as described above. The net relative fluorescence units (RFU) is calculated as the difference between the fluorescence
25 intensities of MRSA and MSSA.

The Fluoroskan plate reader was used to measure the fluorescence in the initial clinical screen of 58 isolates. These results are summarized in Figure 5 as a frequency distribution histogram. Briefly, these results show that the MRSA and MSSA isolates could easily be differentiated as two non-overlapping populations and it
30 was concluded that the assay had 100% sensitivity and 100% specificity for detection of the *mecA* gene relative to culture and PCR resolution (see Example 5).

In a subsequent assay, *S. aureus* isolates (either MSSA or MRSA), were assayed by the DFA using 1 pmol of probe, with the Beacon-2000 tube fluorometer. The screening results of 120 isolates using the Beacon-2000 are shown in Figure 6. The
35 range of MSSA samples are 58.1 – 101.7 RFU and the range of MRSA samples are

144.2 - 191.9, with a net gap between the highest MSSA sample and the lowest MRSA of 42.5 RFU. In this screen, one susceptible isolate was mis-identified as a resistant isolate, giving 100% sensitivity and 98% specificity. This mis-identification was due to incomplete lysis of an MSSA sample. This strain was correctly identified when it was re-tested using a longer lysis time (data not shown).

The above example demonstrates that the *mecA*945-29 probe sequence is very specific and sensitive for detection of *mecA* gene of staphylococci species in crude lysates using the direct CPT fluorescence assay.

10

EXAMPLE 10

The following example demonstrates the utility of CPT for rapid detection of PCR amplicons after a low number of PCR cycles.

The *mecA* gene from MRSA was used as a model system. Initially PCR is carried out and then followed by CPT and detection is carried out by an enzyme immunoassay (CPT-EIA). The CPT-EIA assay has been described previously in Example 7 and illustrated in Figure 3. The procedure for amplicon detection by CPT-EIA is summarized in Fig. 7.

Crude lysates of MSSA (ATCC 11632) and MRSA (ATCC 33592) strains were grown overnight at 37°C on tryptic soy agar with 5% sheep blood (PML Microbiologicals, Tualatin, OR). A cell suspension was made in TES buffer (20 mM TES (pH 6.8), 0.05% Triton X-100) to obtain a cell density equivalent to a 5x McFarland#5 standard of turbidity (7.5×10^9 cells/ml). The cells were lysed with 150 U/ml achromopeptidase (Wako) for 25 min at 37°C. After lysis, the cells were stored at -20°C. Adequate dilutions were made in deionized sterile water.

The PCR reaction was carried out in a 25 µl reaction containing 20 mM Tris, (pH 8.3) 1.5 mM MgCl₂, 0.2 mM dNTPs (Pharmacia), 6.25 pmol of each primer (Table 1) and 0.5 U AmpliTaq Gold (Perkin Elmer). The PTC-100 Programmable Thermal Cycler (MJ Research, Inc.) was used with the following PCR program: 95°C for 10 min., 20x (94°C for 40 s, 53°C for 40 s and 72°C for 1.5 min). The reaction was submitted to a final extension step at 72°C for 5 min. and then held at 4°C prior to analysis. PCR reactions were analyzed by CPT as described below or using a 2 % agarose gel and ethidium bromide (Et-Br) staining.

The 227 bp *mecA* PCR product was used as a standard to determine the sensitivity of CPT-EIA and Et-Br stained gels. The amplicon was prepared as follows: several 100 µl reactions were subjected to 30 cycle PCR and the amplicon was purified

using a Qiagen PCR purification kit as recommended by the manufacturer. The 227 bp product was quantified by spectrophotometer and used as a standard.

The amount of amplicon products was estimated using the following formula: $N = N_0(1+E)^n$ where N is the number of amplicon molecules, N_0 is the starting amount of target molecules, n is the number of cycles and E is the PCR efficiency.

Table. 4. PCR primers and CPT probe sequences. The letters indicate : uppercase is DNA, lower case is RNA, F is fluorescein and B is biotin.

Name	SEQ ID NO.	Sequence 5' to 3'
mecA834-25	9	TGGTAAAAAGGGACTCGAAAAACTT
mecAL1039-22	10	GGTGGATAGCAGTACCTGAGCC
FmecA945-29B	5	F-AATAGAGAAAAAGaaaaAAGATGGCAAAG-B

CPT-EIA. The 25 μ l PCR reaction was heat denatured at 95°C for 2 min and then placed at 54°C. The CPT components in 25 μ l were added to the PCR reaction to give a CPT reaction volume of 50 μ l. In addition to the PCR components, the reaction contained: 20 mM TES, pH 6.8, 4 mM $MgCl_2$, 0.05%, Triton X-100, 1 mM EGTA, 1 mM Spermine, 10 fmol FmecA945-29B probe (Table 4) and 1.42 μ g RNase H. The CPT reaction was incubated at 54°C for 30 min. and stopped with 100 μ l of binding reagent containing 1/600 dilution of anti-fluorescein-HRP (NEN, Boston, MA) conjugate in Peroxidase Stabilizing Buffer (DAKO, Mississauga, ON).

After removal from 54°C, the samples were allowed to cool for 3 minutes at room temperature. The samples were then transferred to streptavidin coated strip well (Boehringer Mannheim) and incubated at room temperature for 10 min. with shaking. The wells were washed 2x with wash buffer (137 mM NaCl, 2.7mM KCl, 1.8 mM KH_2PO_4 , 10.1 mM Na_2HPO_4 , 0.5% Tween 20, 20 ppm ProClin 300, pH7.3) and then 200 μ l of Single Component TMB Peroxidase EIA substrate (Biorad, Hercules, CA) was added. After 3 minutes, color development was halted using detection stop reagent (750 mM Tris, 1.5% SDS, 20 ppm ProClin 300, pH 7.7) and the plates were read at OD 650 nm using a Vmax spectrophotometer (Molecular Devices, Sunnyvale, CA). The net OD_{650} ($=OD_{control} - OD_{sample}$) was used to characterize the presence of specific target. The number of times the target is cycled (T) was estimated as follows: $T = \# \text{ molecules cleaved} / \text{number of target molecules}$.

It was found that the detection sensitivity of CPT-EIA using the standard mecA 227 bp amplicon was 50 amol or 7.6 pg (Figure 8A?). Using the same amplicon, the limit of detection using Et-Br stained agarose gel was 50,000 amol or 7.6 ng (Fig. 8B?). The sensitivity of CPT EIA detection was therefore 3 logs better than that of Et-Br detection. Furthermore, it took approximately 1 hour to analyze the standard

amplicons by CPT-EIA compared to 1.5 hours for the analysis by gel. The analysis by CPT-EIA is semi-quantitative whereas the analysis by gel is qualitative.

5 CPT-EIA was carried out using PCR amplicon prepared from a serial dilution of crude lysates of MSSA and MRSA. The results in Figure 9 showed that CPT-EIA could detect amplicon from a 20 cycle PCR reaction starting with 100 cells or more of MRSA. The signal observed with MSSA was equivalent to background. Similar reactions analyzed by gel required PCR reactions starting with 100,000 cells to detect a band with Et-Br staining. (Figure 10).

10 It was estimated that 80% of probe was cleaved with the 100 MRSA cell equivalent samples. Assuming that the efficiency of PCR is 100%, the number of molecules generated in the reaction would be 175 amol. Thus, the number of times the target is cycled in CPT is at least 50. With this amplification, it is possible to use significantly less cycles (20) than a regular PCR experiment (30 or more cycles). Using fewer cycles has two advantages. The first is that the chance of amplicon carry over is
15 reduced, as mentioned above and second, is that the time for the PCR reaction is shortened by 1 hour. Although very rapid thermocyclers have been developed recently, most thermocyclers require approximately 3 hours for a 30 cycle PCR compared to 2 hours for 20 cycles. The total time required for PCR-CPT is under 3 hours.

20 The number of PCR cycles was varied between 20 and 40 using 100 MRSA or MSSA cell equivalents. CPT-EIA detected MRSA samples after 20 cycles of PCR (Fig. 11A) whereas gel agarose analysis detected sample only after 30 cycles (Fig. 11B). The theoretical difference in the number of amplicon generated in 20 versus 30 PCR cycles is 175 amol compared to 175 fmol, respectively. This corresponds to a 1000-fold difference in sensitivity, which is in agreement with the experiments
25 described above.

It was possible to visually discriminate the presence or absence of specific target without the requirement of an instrument (data not shown). The presence of the specific target is indicated by a very light or absence of blue color due to cleavage of the probe whereas the absence of target results in a dark blue color.

30 In addition to its speed and reduced risk of contamination, PCR-CPT adds a second level of specificity to PCR. Indeed, CPT is based on hybridization and under the conditions used, non-specific amplicon will not be detected. This method is a step forward and may eliminate the use of Southern or nested PCR in certain applications, and use of highly specialized detection means.

35 CPT allows rapid and accurate detection of PCR amplicons. In addition, CPT adds a second level of amplification but without further amplifying the target, and

therefore it is possible to use significantly less number PCR cycles. This will reduce the chance of contamination and false positive. CPT adds a second level of specificity which will prevent detection of non-specific amplicons and primer-dimers. The PCR-CPT method may also be used for mismatch gene detection.

5

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

10

CLAIMS

We claim:

1. A method for determining the presence of an antibiotic resistant *mecA* gene in a biological sample, comprising:

(a) treating cells contained within a biological sample to expose target single-stranded nucleic acid molecules;

(b) reacting said target single-stranded nucleic acids with a scissile link-containing nucleic acid probe which is complementary to a portion of an antibiotic resistant *mecA* gene, and with an enzyme which cleaves double-stranded target-probe complexes, under conditions which allow the target and probe to hybridize to each other to form a double-stranded target-probe complex, said enzyme molecule being capable of cleaving said scissile link of said target-probe complex such that one or more fragments of the nucleic acid probe are released from said complex; and

(c) determining whether cleaved portions of said nucleic acid probe are produced, and thereby detecting the presence of an antibiotic resistant *mecA* gene.

2. The method according to claim 1 wherein the step of determining comprises detecting a decrease in the amount of uncleaved probe, and thereby determining whether the cleaved portions of said nucleic acid probe are produced.

3. The method according to claim 1 wherein the step of determining comprises directly detecting cleaved portions of the nucleic acid probe.

4. The method according to claim 1, wherein said probe consists essentially of at least a portion of the nucleotide sequence GACGATAATA GCAATACAAT CGCACATACA TTAATAGAGA AAAAGAAAAA AGATGGCAAA GATATTCAAC TAACTATTGA TGCTAAAGTT CAAAAGAGTA TTTATAAC (SEQ ID NO:13).

5. The method according to claim 1 wherein said probe consists essentially of at least a portion of the nucleotide sequence GAACTTTAGC ATCAATAGTT AGTTGAATAT CTTTGCCATC TTTTCTTT TTCTCTATTA ATGTATGTGC GATTGTATTG CTATTATCG (SEQ ID NO:4).

6. The method according to claim 2 wherein said probe has the nucleotide sequence AATAGAGAAA AAGAAAAAAG ATGGCAAAG (SEQ ID NO:1).

7. The method according to claim 1 wherein said probe consists essentially of the nucleotide sequence AATAGAGaaaaAGAAAAA AGATGGCAAAG-3' (SEQ ID NO:5); wherein large letters represent deoxyribonucleotides and small letters represent ribonucleotides.

8. The method of claim 1 wherein the *mecA* gene is from a staphylococcal species.

9. The method of claim 8 wherein the *mecA* gene is from a coagulase positive staphylococcal species.

10. The method of claim 9 wherein the *mecA* gene is from *S. aureus*.

11. The method of claim 8 wherein the *mecA* gene is from the group consisting of coagulase negative staphylococcal species.

12. The method of claim 11 wherein the *mecA* gene is from *S. epidermidis*.

13. The method of claim 1 wherein the biological sample is selected from the group consisting of a nasal swab, blood, urine, stool, abscess and spinal fluid.

14. The method of claim 1 wherein the biological sample was first grown or isolated on a bacteriological growth medium.


15. A probe for detecting the presence of an antibiotic resistant *mecA* gene in a biological sample, wherein said probe comprises the sequence GACGATAATA GCAATACAAT CGCACATACA TTAATAGAGA AAAAGAAAAA AGATGGCAAA GATATTCAAC TAACTATTGA TGCTAAAGTT CAAAAGAGTA TTTATAAC (SEQ ID NO:13).

16. A kit for detecting the presence of an antibiotic resistant *mecA* gene in a biological sample, comprising (a) one or more scissile-link containing nucleic acid probes, and (b) an enzyme capable of cleaving the scissile link when said probe is bound to a target.

17. The kit according to claim 16 wherein said enzyme is RNaseH.

18. The kit according to claim 16 wherein said *mecA* gene is from a staphylococcal species.

1/10

*Fig. 1*

2/10




Fig. 2

3/10




Fig. 3

4/10

Frequency Distribution of 102 *S. aureus* clinical isolates based on detection of the *mecA* gene by Subtractive CPT Assay




Fig. 4

5/10

Frequency distribution of 58 *S. aureus* clinical isolates based on detection of the *mecA* gene by CPT Direct Fluorescence Assay using the plate format




Fig. 5

6/10

Frequency distribution of 120 *S. aureus* clinical isolates based on detection of the *mecA* gene
by CPT Direct Fluorescence Assay using single tube format





Fig. 6

7/10

PCR-CPT procedure

*Fig. 7*




Fig. 8A




Fig. 8B




Fig. 9A




Fig. 9B




Fig. 10A




Fig. 10B

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANTS: Bekkaoui, Faouzi
Cloney, Lynn P.
- (ii) TITLE OF INVENTION: METHODS FOR RAPIDLY DETECTING METHICILLIN
RESISTANT STAPHYLOCOCCI
- (iii) NUMBER OF SEQUENCES: 26
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: SEED and BERRY LLP
 - (B) STREET: 6300 Columbia Center, 701 Fifth Avenue
 - (C) CITY: Seattle
 - (D) STATE: Washington
 - (E) COUNTRY: USA
 - (F) ZIP: 98104
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: US
 - (B) FILING DATE: 22-JUN-1998
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: McMasters, David D.
 - (B) REGISTRATION NUMBER: 33,963
 - (C) REFERENCE/DOCKET NUMBER: 480094.424P3
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (206) 622-4900
 - (B) TELEFAX: (206) 682-6031

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AATAGAGAAA AAGAAAAAAG ATGGCAAAG

29

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CTTTGCCATC TTTTTTCTTT TTCTCTATT

29

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 59 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CGCACAUACA UAAUAGAGA AAAAGAAAAA AGAUGGCAAA GAUAUUAAC UAACUAUUG

59

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 89 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GAACTTTAGC ATCAATAGTT AGTTGAATAT CTTTGCCATC TTTTTTCTTT TTCTCTATTA

60

ATGTATGTGC GATTGTATTG CTATTATCG

89

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 14..17
- (D) OTHER INFORMATION: /note= "Where N is an adenine ribonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

AATAGAGAAA AAGNNNNAAG ATGGCAAAG

29

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 47 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AATAGAGAAA AAGAAAAAAG ATGGCAAAGA AAAAAAAAAA AAAAAA

47

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 14..17
- (D) OTHER INFORMATION: /note= "Where N is an adenine ribonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

AATAGAGAAA AAGNNNNAAG ATGGCAAAG

29

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 29 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

AAUAGAGAAA AAGAAAAAG AUGGCAAAG

29

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

TGGTAAAAAG GGACTCGAAA AACTT

25

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 22 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GGTGGATAGC AGTACCTGAG CC

22

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 29 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

AGCTCCAACA TGAAGATGGC TATCGTGTC

29

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

ACCTGTTTGA GGGTGGATAG CAGTACCTGA

30

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 108 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GACGATAATA GCAATACAAT CGCACATACA TTAATAGAGA AAAAGAAAAA AGATGGCAAA

60

GATATTCAAC TAACTATTGA TGCTAAAGTT CAAAAGAGTA TTTATAAC

108

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

ATACATTAAT AGAGAAAAAG AAAAAAGATG GCAAAG

36

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 15..18
- (D) OTHER INFORMATION: /note= "Where N is an adenine ribonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

ATCCATTAAT AGAGNNNNAG AAAAAAGATG GCAAAG

36

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

ACGGAGAAGA AGTTGTAGCA GG

22

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GGTGAAGTAG AAATGACTGA ACGTCCG

27

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

AAGATGGTAT GTGGAAGTTA GATTG

25

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

GATGGTATGT GGAAGTTAGA TTGG

24

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 26 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

TGGTATGTGG AAGTTAGATT GGGATC

26

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 27 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

ATGCAGTTAT TGGTAAAAAG GGACTCG

27

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

TGTTTAGGGT GGATAGCAGT AC

22

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GAUAACAUUU UCUUJGCUAG AGUAG

25

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 28 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

This Page Blank (uspto)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68	A3	(11) International Publication Number: WO 99/01572 (43) International Publication Date: 14 January 1999 (14.01.99)
(21) International Application Number: PCT/CA98/00633 (22) International Filing Date: 3 July 1998 (03.07.98) (30) Priority Data: 60/051,643 3 July 1997 (03.07.97) US 60/086,020 18 May 1998 (18.05.98) US 60/090,276 22 June 1998 (22.06.98) US (71) Applicant (for all designated States except US): ID BIOMEDICAL CORPORATION [CA/CA]; 8855 Northbrook Court, Burnaby, British Columbia V5J 5G1 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): BEKKAOUI, Faouzi [CA/CA]; 3877 Gilpin Street, Burnaby, British Columbia V5G 2H2 (CA). CLONEY, Lynn, P. [CA/CA]; 5438 Elizabeth Street, Vancouver, British Columbia V5Y 3J8 (CA). (74) Agents: NASSIF, Omar, A. et al.; Gowling, Strathy & Henderson, Suite 4900, Commerce Court West, Toronto, Ontario M5L 1J3 (CA).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 25 March 1999 (25.03.99)
(54) Title: METHODS FOR RAPIDLY DETECTING METHICILLIN RESISTANT STAPHYLOCOCCI (57) Abstract <p>Compositions and methods are provided for determining the presence of an antibiotic resistant <i>mecA</i> gene in a biological sample, comprising the general steps of (a) treating cells contained within a biological sample to expose target single-stranded nucleic acid molecules; (b) reacting the target single-stranded nucleic acids with a scissile link-containing nucleic acid which is complementary to a portion of an antibiotic resistant <i>mecA</i> gene, and with an enzyme which cleaves double-stranded target-probe complexes, under conditions which allow the target and probe to hybridize to each other to form a double-stranded target-probe complex, the enzyme molecule being capable of cleaving the scissile link of the target-probe complex such that one or more fragments of the nucleic acid probe released from said complex; and (c) determining whether cleaved portions of the detecting probe fragments released from said nucleic acid probe are produced, and thereby detecting the presence of the antibiotic resistant <i>mecA</i> gene.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

In: tional Application No
PCT/CA 98/00633

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CLONEY ET AL.: "RAPID DETECTION OF THE mecA GENE IN CLINICAL ISOLATES USING A NOVEL DNA-PROBE ASSAY" ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 97, 4 - 8 May 1997, page 171 XP002089034	1-3, 8-14, 16-18
Y	see the whole document ---	4-7, 15
Y	EP 0 527 628 A (LILLY CO ELI) 17 February 1993 see the whole document ---	1-18
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

7 January 1999

Date of mailing of the international search report

21/01/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Hagenmaier, S

INTERNATIONAL SEARCH REPORT

Int. Patent Application No

PCT/CA 98/00633

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DUCK ET AL.: "PROBE AMPLIFIER SYSTEM BASED ON CHIMERIC CYCLING OLIGONUCLEOTIDES" BIOTECHNIQUES, vol. 9, 1990, pages 142-147, XP000406092 see the whole document	1-18
Y	US 5 011 769 A (BENDER ROBERT ET AL) 30 April 1991 see the whole document	1-18
Y	US 5 403 711 A (WALDER JOSEPH A ET AL) 4 April 1995 see the whole document	1-18
Y	DE 43 38 119 A (BAYER AG) 11 May 1995 see the whole document	1-18
A	WO 97 11199 A (LANE MICHAEL J ; BENIGHT ALBERT S (US); FALDASZ BRIAN D (US)) 27 March 1997 see the whole document	1-18
A	WO 95 05480 A (BEKKAOUI FAOUZI ; DUCK PETER D (CA); CROSBY WILLIAM L (CA); ID BIOM) 23 February 1995 see the whole document	1-18
A	PATENT ABSTRACTS OF JAPAN vol. 097, no. 002, 28 February 1997 & JP 08 252099 A (WAKUNAGA PHARMACEUT CO LTD), 1 October 1996 see abstract	1-18
P, X	FULLER ET AL.: "RAPID DETECTION OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) USING CYCLING PROBE TECHNOLOGY (CPT)" ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 98, 17 - 21 May 1998, page 199 XP002089036 see the whole document	1-3, 8-14, 16-18
P, A	DATABASE EMBL ID/AC: V36396, 22 May 1998 BAKER ET AL.: "NEW SYNTHETIC OLIGONUCLEOTIDE ANTISENSE TO MULTI-DRUG RESISTANCE GENE OF PLASMODIUM" XP002089363 see abstract	4-7, 15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 98/00633

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0527628 A	17-02-1993	AT 140036 T CA 2075423 A DE 69211921 D DE 69211921 T DK 527628 T ES 2089409 T GR 3020506 T JP 5329000 A	15-07-1996 14-02-1993 08-08-1996 12-12-1996 29-07-1996 01-10-1996 31-10-1996 14-12-1993
US 5011769 A	30-04-1991	US 4876187 A AU 3569789 A DK 665889 A EP 0365663 A JP 2504110 T WO 8910415 A AU 601383 B AU 6610886 A CA 1304703 A EP 0227976 A FI 864964 A JP 2742905 B JP 8242896 A JP 2691177 B JP 62190086 A	24-10-1989 24-11-1989 02-02-1990 02-05-1990 29-11-1990 02-11-1989 13-09-1990 11-06-1987 07-07-1992 08-07-1987 06-06-1987 22-04-1998 24-09-1996 17-12-1997 20-08-1987
US 5403711 A	04-04-1995	AU 623642 B AU 3294489 A DE 68911648 D DE 68911648 T EP 0365627 A WO 8909284 A AT 151467 T AU 2782989 A CA 1339935 A DE 3855864 D DE 3855864 T EP 0348458 A JP 2502516 T WO 8905358 A US 5491133 A	21-05-1992 16-10-1989 03-02-1994 23-06-1994 02-05-1990 05-10-1989 15-04-1997 05-07-1989 30-06-1998 15-05-1997 25-09-1997 03-01-1990 16-08-1990 15-06-1989 13-02-1996
DE 4338119 A	11-05-1995	WO 9513395 A	18-05-1995
WO 9711199 A	27-03-1997	AU 7368596 A	09-04-1997
WO 9505480 A	23-02-1995	AU 7487294 A CA 2169837 A EP 0716713 A JP 9506762 T US 5731146 A	14-03-1995 23-02-1995 19-06-1996 08-07-1997 24-03-1998

This Page Blank (uspto)